The  	The  	 DT	O
chemokine  	chemokine  	 JJ	B-NP
system  	system  	 NN	I-NP
and  	and  	 CC	O
its  	its  	 PRP$	O
contribution  	contribution  	 NN	B-NP
to  	to  	 TO	O
leukemogenesis  	leukemogenesis  	 VB	O
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
responsiveness  	responsiveness  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
acute  	acute  	 JJ	O
myeloid  	myeloid  	 NNS	B-NP
leukemia  	leukemia  	 VBP	I-NP
The  	The  	 DT	O
chemokine  	chemokine  	 JJ	B-NP
family  	family  	 NN	I-NP
consists  	consists  	 VBZ	O
of  	of  	 IN	O
approximately  	approximately  	 RB	O
50  	50  	 CD	O
small  	small  	 JJ	O
( 	( 	 -LRB-	O
8-14  	8-14  	 NNP	O
kDa 	kDa 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
basic  	basic  	 JJ	O
proteins  	proteins  	 NNS	O
that  	that  	 WDT	O
are  	are  	 VBP	O
expressed  	expressed  	 VBN	O
and  	and  	 CC	O
released  	released  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
range  	range  	 NN	O
of  	of  	 IN	O
normal  	normal  	 JJ	O
and  	and  	 CC	O
malignant  	malignant  	 JJ	O
cells 	cells 	 NNS	O
.  	.  	 .	O
Most  	Most  	 RBS	O
chemokines  	chemokines  	 JJ	B-NP
act  	act  	 NN	I-NP
through  	through  	 IN	O
heptahelical  	heptahelical  	 FW	B-NP
transmembrane  	transmembrane  	 FW	I-NP
G  	G  	 FW	I-NP
protein-  	protein-  	 FW	I-NP
coupled  	coupled  	 FW	I-NP
receptors 	receptors 	 FW	I-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
their  	their  	 PRP$	O
molecular  	molecular  	 JJ	B-NP
structure  	structure  	 NN	I-NP
these  	these  	 DT	O
cytokines  	cytokines  	 NNS	B-NP
are  	are  	 VBP	O
divided  	divided  	 VBN	O
into  	into  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
major  	major  	 JJ	O
subgroups  	subgroups  	 JJ	B-NP
CCL  	CCL  	 NNP	O
and  	and  	 CC	O
CXCL  	CXCL  	 NNP	O
chemokines  	chemokines  	 NN	B-NP
that  	that  	 IN	O
bind  	bind  	 NN	O
to  	to  	 TO	O
CCR  	CCR  	 NNP	B-NP
or  	or  	 CC	O
CXCR  	CXCR  	 NNP	B-NP
receptors  	receptors  	 VBD	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Primary  	Primary  	 JJ	B-NP
human  	human  	 JJ	I-NP
acute  	acute  	 JJ	I-NP
myelogenous  	myelogenous  	 JJ	I-NP
leukemia  	leukemia  	 NN	I-NP
( 	( 	 -LRB-	O
AML 	AML 	 NNP	B-NP
)  	)  	 -RRB-	O
cells  	cells  	 NNS	O
show  	show  	 VBP	O
constitutive  	constitutive  	 JJ	B-NP
release  	release  	 NN	I-NP
of  	of  	 IN	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
range  	range  	 NN	O
of  	of  	 IN	O
chemokines 	chemokines 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
chemokine  	chemokine  	 JJ	B-NP
release  	release  	 NN	I-NP
profile  	profile  	 NN	I-NP
differs  	differs  	 VBZ	O
between  	between  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
Among  	Among  	 IN	O
the  	the  	 DT	O
commonly  	commonly  	 RB	O
expressed  	expressed  	 VBN	B-NP
chemokines  	chemokines  	 NNS	I-NP
are  	are  	 VBP	O
proangiogenic  	proangiogenic  	 JJ	B-NP
CXCL8 	CXCL8 	 NN	I-NP
,  	,  	 ,	O
antiangiogenic  	antiangiogenic  	 CD	B-NP
CXCL4 	CXCL4 	 CD	I-NP
/ 	/ 	 CD	O
9-11  	9-11  	 CD	O
and  	and  	 CC	O
several  	several  	 JJ	O
leukocyte-chemotactic  	leukocyte-chemotactic  	 JJ	B-NP
chemokines 	chemokines 	 NN	I-NP
.  	.  	 .	O
Systemic  	Systemic  	 JJ	B-NP
serum  	serum  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
of  	of  	 IN	I-NP
leukocyte-chemotactic  	leukocyte-chemotactic  	 JJ	I-NP
chemokines  	chemokines  	 NNS	I-NP
depend  	depend  	 VBP	O
both  	both  	 DT	O
on  	on  	 IN	O
patient  	patient  	 JJ	O
age 	age 	 NN	O
,  	,  	 ,	O
disease  	disease  	 NN	B-NP
status 	status 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
chemotherapy  	chemotherapy  	 JJ	O
regimen  	regimen  	 NN	O
and  	and  	 CC	O
development  	development  	 NN	O
of  	of  	 IN	O
complicating  	complicating  	 JJ	O
infections 	infections 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
local  	local  	 JJ	O
chemokine  	chemokine  	 JJ	B-NP
network  	network  	 NN	I-NP
in  	in  	 IN	O
human  	human  	 JJ	O
AML  	AML  	 NNP	B-NP
is  	is  	 VBZ	O
probably  	probably  	 RB	O
further  	further  	 JJ	O
modulated  	modulated  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
hypoxic  	hypoxic  	 JJ	B-NP
bone  	bone  	 NN	I-NP
marrow  	marrow  	 NN	I-NP
microenvironment  	microenvironment  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
local  	local  	 JJ	O
release  	release  	 NN	O
of  	of  	 IN	O
chemokines  	chemokines  	 NN	B-NP
by  	by  	 IN	O
nonleukemic  	nonleukemic  	 JJ	B-NP
bone  	bone  	 NN	I-NP
marrow  	marrow  	 NN	I-NP
stromal  	stromal  	 NN	I-NP
cells 	cells 	 NNS	I-NP
.  	.  	 .	O
Usually  	Usually  	 RB	O
primary  	primary  	 JJ	B-NP
AML  	AML  	 NN	I-NP
cells  	cells  	 NNS	I-NP
also  	also  	 RB	O
express  	express  	 VB	O
several  	several  	 JJ	O
chemokine  	chemokine  	 JJ	B-NP
receptors 	receptors 	 NNS	I-NP
.  	.  	 .	O
Specific  	Specific  	 JJ	B-NP
chemokine  	chemokine  	 JJ	I-NP
inhibitors  	inhibitors  	 NNS	I-NP
are  	are  	 VBP	O
now  	now  	 RB	O
being  	being  	 VBG	O
developed 	developed 	 VBN	O
,  	,  	 ,	O
including  	including  	 VBG	B-NP
chemokine-neutralizing  	chemokine-neutralizing  	 JJ	I-NP
or  	or  	 CC	O
receptor-blocking  	receptor-blocking  	 JJ	B-NP
antibodies 	antibodies 	 NNS	I-NP
,  	,  	 ,	O
antisense  	antisense  	 JJ	B-NP
strategies 	strategies 	 NNS	I-NP
,  	,  	 ,	O
receptor-blocking  	receptor-blocking  	 JJ	B-NP
small  	small  	 JJ	O
molecules  	molecules  	 NNS	O
or  	or  	 CC	O
inhibitors  	inhibitors  	 NN	O
of  	of  	 IN	O
downstream  	downstream  	 JJ	O
signaling 	signaling 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
CXCR4-antagonists  	CXCR4-antagonists  	 CD	B-NP
for  	for  	 IN	I-NP
mobilization  	mobilization  	 NN	I-NP
of  	of  	 IN	I-NP
peripheral  	peripheral  	 JJ	I-NP
blood  	blood  	 NN	I-NP
stem  	stem  	 NN	I-NP
cells  	cells  	 NNS	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
documented  	documented  	 VBN	O
in  	in  	 IN	O
several  	several  	 JJ	O
clinical  	clinical  	 JJ	B-NP
studies 	studies 	 NNS	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
animal  	animal  	 JJ	O
studies  	studies  	 NNS	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
chemokine  	chemokine  	 JJ	B-NP
inhibition  	inhibition  	 NNS	I-NP
also  	also  	 RB	O
may  	may  	 MD	O
become  	become  	 VB	O
useful  	useful  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
graft  	graft  	 FW	O
versus  	versus  	 FW	O
host  	host  	 NN	B-NP
disease 	disease 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
possible  	possible  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
chemokine-targeting  	chemokine-targeting  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	O
other  	other  	 JJ	O
indications  	indications  	 NNS	O
than  	than  	 IN	O
stem  	stem  	 JJ	O
cell  	cell  	 NN	O
mobilization  	mobilization  	 NN	O
requires  	requires  	 VBZ	O
further  	further  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
